Cargando…
Comparative Evaluation of Engineered Polypeptide Scaffolds in HER2-Targeting Magnetic Nanocarrier Delivery
[Image: see text] Targeted drug delivery is one of the most intriguing and challenging issues in modern biomedicine. For active targeting, full-size IgG molecules (150 kDa) are usually used. Recent studies have revealed that small artificial polypeptide scaffolds such as DARPins (14 kDa) and affibod...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223436/ https://www.ncbi.nlm.nih.gov/pubmed/34179645 http://dx.doi.org/10.1021/acsomega.1c01811 |
_version_ | 1783711693224804352 |
---|---|
author | Shipunova, Victoria O. Kolesnikova, Olga A. Kotelnikova, Polina A. Soloviev, Vladislav D. Popov, Anton A. Proshkina, Galina M. Nikitin, Maxim P. Deyev, Sergey M. |
author_facet | Shipunova, Victoria O. Kolesnikova, Olga A. Kotelnikova, Polina A. Soloviev, Vladislav D. Popov, Anton A. Proshkina, Galina M. Nikitin, Maxim P. Deyev, Sergey M. |
author_sort | Shipunova, Victoria O. |
collection | PubMed |
description | [Image: see text] Targeted drug delivery is one of the most intriguing and challenging issues in modern biomedicine. For active targeting, full-size IgG molecules (150 kDa) are usually used. Recent studies have revealed that small artificial polypeptide scaffolds such as DARPins (14 kDa) and affibodies (8 kDa) are much more promising tools for drug delivery due to their small size, artificial nature, low immunogenicity, and many other properties. However, there is no comparative information on the targeting abilities of scaffold polypeptides, which should be taken into account when developing drug delivery systems (DDSs). The present work is the first comprehensive study on the comparison of the effectiveness of different HER2-targeting proteins within the architecture of nanoparticles. Namely, we synthesized trimodal nanoparticles: magnetic, fluorescent, and directed toward HER2 oncomarker on cancer cells. The magnetic particles (MPs) were covalently modified with (i) full-size IgG, 150 kDa, (ii) DARPin_G3, 14 kDa, and (iii) affibody Z(HER2:342), 8 kDa. We showed that the number of DARPin_G3 and affibody Z(HER2:342) molecules conjugated to the nanoparticle surface are 10 and 40 times higher, respectively, than the corresponding value for trastuzumab. Using the methods of magnetic particle quantification (MPQ)-cytometry and confocal microscopy, we showed that all types of the obtained magnetic conjugates specifically labeled HER2-overexpressing cells. Namely, we demonstrated that particle binding to HER2-positive cells is 1113 ± 39 fg/cell for MP*trastuzumab, 1431 ± 186 fg/cell for MP*Z(HER2:342), and 625±21 fg/cell for MP*DARPin_G3, which are 2.77, 2.75, and 2.30 times higher than the corresponding values for control HER2-negative cells. Thus, we showed that the smallest HER2-recognizing polypeptide affibody Z(HER2:342) is more effective in terms of specificity and selectivity in nanoparticle-mediated cell labeling. |
format | Online Article Text |
id | pubmed-8223436 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-82234362021-06-25 Comparative Evaluation of Engineered Polypeptide Scaffolds in HER2-Targeting Magnetic Nanocarrier Delivery Shipunova, Victoria O. Kolesnikova, Olga A. Kotelnikova, Polina A. Soloviev, Vladislav D. Popov, Anton A. Proshkina, Galina M. Nikitin, Maxim P. Deyev, Sergey M. ACS Omega [Image: see text] Targeted drug delivery is one of the most intriguing and challenging issues in modern biomedicine. For active targeting, full-size IgG molecules (150 kDa) are usually used. Recent studies have revealed that small artificial polypeptide scaffolds such as DARPins (14 kDa) and affibodies (8 kDa) are much more promising tools for drug delivery due to their small size, artificial nature, low immunogenicity, and many other properties. However, there is no comparative information on the targeting abilities of scaffold polypeptides, which should be taken into account when developing drug delivery systems (DDSs). The present work is the first comprehensive study on the comparison of the effectiveness of different HER2-targeting proteins within the architecture of nanoparticles. Namely, we synthesized trimodal nanoparticles: magnetic, fluorescent, and directed toward HER2 oncomarker on cancer cells. The magnetic particles (MPs) were covalently modified with (i) full-size IgG, 150 kDa, (ii) DARPin_G3, 14 kDa, and (iii) affibody Z(HER2:342), 8 kDa. We showed that the number of DARPin_G3 and affibody Z(HER2:342) molecules conjugated to the nanoparticle surface are 10 and 40 times higher, respectively, than the corresponding value for trastuzumab. Using the methods of magnetic particle quantification (MPQ)-cytometry and confocal microscopy, we showed that all types of the obtained magnetic conjugates specifically labeled HER2-overexpressing cells. Namely, we demonstrated that particle binding to HER2-positive cells is 1113 ± 39 fg/cell for MP*trastuzumab, 1431 ± 186 fg/cell for MP*Z(HER2:342), and 625±21 fg/cell for MP*DARPin_G3, which are 2.77, 2.75, and 2.30 times higher than the corresponding values for control HER2-negative cells. Thus, we showed that the smallest HER2-recognizing polypeptide affibody Z(HER2:342) is more effective in terms of specificity and selectivity in nanoparticle-mediated cell labeling. American Chemical Society 2021-06-10 /pmc/articles/PMC8223436/ /pubmed/34179645 http://dx.doi.org/10.1021/acsomega.1c01811 Text en © 2021 The Authors. Published by American Chemical Society Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Shipunova, Victoria O. Kolesnikova, Olga A. Kotelnikova, Polina A. Soloviev, Vladislav D. Popov, Anton A. Proshkina, Galina M. Nikitin, Maxim P. Deyev, Sergey M. Comparative Evaluation of Engineered Polypeptide Scaffolds in HER2-Targeting Magnetic Nanocarrier Delivery |
title | Comparative Evaluation of Engineered Polypeptide Scaffolds
in HER2-Targeting Magnetic Nanocarrier Delivery |
title_full | Comparative Evaluation of Engineered Polypeptide Scaffolds
in HER2-Targeting Magnetic Nanocarrier Delivery |
title_fullStr | Comparative Evaluation of Engineered Polypeptide Scaffolds
in HER2-Targeting Magnetic Nanocarrier Delivery |
title_full_unstemmed | Comparative Evaluation of Engineered Polypeptide Scaffolds
in HER2-Targeting Magnetic Nanocarrier Delivery |
title_short | Comparative Evaluation of Engineered Polypeptide Scaffolds
in HER2-Targeting Magnetic Nanocarrier Delivery |
title_sort | comparative evaluation of engineered polypeptide scaffolds
in her2-targeting magnetic nanocarrier delivery |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223436/ https://www.ncbi.nlm.nih.gov/pubmed/34179645 http://dx.doi.org/10.1021/acsomega.1c01811 |
work_keys_str_mv | AT shipunovavictoriao comparativeevaluationofengineeredpolypeptidescaffoldsinher2targetingmagneticnanocarrierdelivery AT kolesnikovaolgaa comparativeevaluationofengineeredpolypeptidescaffoldsinher2targetingmagneticnanocarrierdelivery AT kotelnikovapolinaa comparativeevaluationofengineeredpolypeptidescaffoldsinher2targetingmagneticnanocarrierdelivery AT solovievvladislavd comparativeevaluationofengineeredpolypeptidescaffoldsinher2targetingmagneticnanocarrierdelivery AT popovantona comparativeevaluationofengineeredpolypeptidescaffoldsinher2targetingmagneticnanocarrierdelivery AT proshkinagalinam comparativeevaluationofengineeredpolypeptidescaffoldsinher2targetingmagneticnanocarrierdelivery AT nikitinmaximp comparativeevaluationofengineeredpolypeptidescaffoldsinher2targetingmagneticnanocarrierdelivery AT deyevsergeym comparativeevaluationofengineeredpolypeptidescaffoldsinher2targetingmagneticnanocarrierdelivery |